Not medical advice
First and Subsequent Major Cardiovascular Events With Oral Semaglutide in High-Risk Type 2 Diabetes: A Secondary Analysis of the SOUL Randomized Clinical Trial
Community vote
No Bro-Meter votes yet. Be the first. The verdict is only these votes — not FDA pages, imports, or ads.
Tried-it reports
Lived experience sits next to the community vote. Official sources never override either.
Published in JAMA Cardiol. Imported from PubMed. This was filed by the system importer, not a fake user. Possible receipts (auto-attached from public APIs — verify before trusting): - ClinicalTrials.gov: The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect — https://clinicaltrials.gov/study/NCT06058585 - SEC EDGAR: VERU INC. (VERU) (CIK 0000863894) filed a 8-K — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&dateb=&owner=include&count=10&search_text=0001193125-26-384430
Not medical advice. We don't sell peptides. Votes and comments are community opinion, not clinical guidance.
Comments
No comments yet. Got receipts? Drop them.